Showing 6571-6580 of 7128 results for "".
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- National Psoriasis Foundation's Patient Registry Begins Recruitinghttps://practicaldermatology.com/news/national-psoriasis-foundations-patient-registry-begins-recruiting/2458999/People with psoriasis and their health care providers will have the opportunity to participate in re
- Cosmederm Bioscience Introduces Steve Massah as New Chief Operating Officerhttps://practicaldermatology.com/news/cosmederm-bioscience-introduces-steve-massah-as-new-chief-operating-officer/2459004/Cosmederm Bioscience has hired Steve Massah as its new Chief Operating Officer. As COO, Massah will provide strategic and tactical leadership, and management of manufacturing, product development, quality and product shipment and logistics. His work will ensure compliance with all government regu
- Actavis Divests Rights to Doryx to Mayne Pharmahttps://practicaldermatology.com/news/actavis-divests-rights-to-doryx-to-mayne-pharma/2459007/Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was
- New App for Clinical Skin Cancer Diagnosis Launches on World Cancer Day 2015; Physician Input Soughthttps://practicaldermatology.com/news/new-app-for-clinical-skin-cancer-diagnosis-launches-on-world-cancer-day-2015-physician-input-sought/2459012/On World Cancer Day 2015, general practitioners, physicians, and dermatologists in the United States, United Kingdom and Australia were asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a role in the clinical detection of skin cancer.
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com
- Oculus Innovative Sciences Launches IntraDerm Pharmaceuticals, New Dermatology Divisionhttps://practicaldermatology.com/news/oculus-innovative-sciences-launches-intraderm-pharmaceuticals-new-dermatology-division/2459028/Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has launched a
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed w